CDC Updates Hepatitis B Vaccine Guidance: Shared Decision-Making for Infants

The Centers for Disease Control and Prevention (CDC) announced a shift in its recommendations for hepatitis B immunization on December 16, 2025. The change centers on allowing individual-based decision-making for parents regarding the hepatitis B vaccine, including the birth dose, for infants born to mothers who have tested negative for the virus.

Understanding the New Guidance

This individual-based decision-making, also referred to as shared clinical decision-making, means parents and their healthcare providers will now discuss the benefits, risks, and potential infection risks before deciding when, or if, to begin the hepatitis B vaccine series. Factors to consider include potential exposure risks, such as a household member with hepatitis B or frequent contact with individuals from areas where hepatitis B is prevalent.

Did You Know? The CDC will update both the child immunization schedule and applicable clinical guidance to reflect these new recommendations.

What Remains Unchanged

For infants born to mothers who test positive for hepatitis B, or whose status is unknown, the current recommendations for the birth dose of the hepatitis B vaccine and immunoglobulin remain in place. There are no changes to these protocols.

Implications and Next Steps

The CDC Advisory Committee on Immunization Practices (ACIP) recently recommended this shift, and Acting Director of the CDC and Deputy Secretary of Health and Human Services Jim O’Neill approved the recommendations today. The CDC is also reviewing a secondary recommendation from ACIP regarding serology testing to determine if a subsequent vaccine dose is needed.

Expert Insight: This change represents a move toward greater parental involvement in vaccination decisions, particularly in cases where the risk of hepatitis B transmission to newborns is considered low. It acknowledges the importance of a balanced discussion between healthcare providers and families.

The CDC has affirmed that this new approach will not disrupt coverage through existing payment mechanisms. Programs like the Vaccines for Children Program, the Children’s Health Insurance Program, Medicaid, Medicare, and insurance plans through the federal Health Insurance Marketplace will continue to cover the cost of the vaccine as appropriate.

Frequently Asked Questions

What does “individual-based decision-making” mean?

Individual-based decision-making, or shared clinical decision-making, means parents and healthcare providers should consider vaccine benefits, risks, and infection risks when deciding whether to begin the hepatitis B vaccine series for an infant.

Are there any changes for infants born to mothers with hepatitis B?

No, the currently recommended birth dose of the hepatitis B vaccine and immunoglobulin continues for infants born to mothers who test positive for hepatitis B or whose status is unknown.

Will insurance continue to cover the hepatitis B vaccine?

Yes, the CDC states that the adoption of individual-based decision-making maintains consistency of coverage through all payment mechanisms, including entitlement programs and insurance plans.

How might this shift in recommendations influence conversations between parents and their pediatricians regarding infant vaccinations?